Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3195 + pembrolizumab in advanced solid tumors
CTR20260447Phase 2Active
- Sponsor
- Zhikang Hongyi
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BC3195 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhikang Hongyi. Started Mar 2026; status: active.
02
Drugs
BC3195
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20260447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260447.